Evaluation of anti α-d -Glcp-(1→4)-α-d -Glcp (GAGA4) IgM antibodies as a biomarker for multiple sclerosis
| Autor: | Anne C. La Flamme, Kristiana T. Santoso, Chriselle D. Braganza, Bridget L. Stocker, Emma M. Dangerfield, Mattie S. M. Timmer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
business.industry Igm antibody General Chemical Engineering Multiple sclerosis Diagnostic test General Chemistry medicine.disease Pathophysiology 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Immunology Medicine Diagnostic biomarker Biomarker (medicine) business 030217 neurology & neurosurgery |
| Zdroj: | RSC Advances. 8:28086-28093 |
| ISSN: | 2046-2069 |
| DOI: | 10.1039/c8ra04897e |
| Popis: | The correct diagnosis of multiple sclerosis (MS) remains challenging due to the complex pathophysiological and clinical characteristics of the disease. Consequently, there has been immense interest in finding a non-invasive diagnostic test for MS. Recent studies found that serum anti-α-D-Glcp-(1→4)-α-D-Glcp (GAGA4) IgM antibodies were upregulated in MS patients, and this finding led to the development of a commercial diagnostic test (gMS® Dx test), although the test has poor selectivity and has not been independently validated. Herein, we developed an enzyme-linked immunosorbent assay (ELISA) to evaluate the use and reliability of several anti-glucose IgM antibodies, including those against GAGA4, as diagnostic biomarkers for MS. In contrast to previous studies, our results show that serum anti-GAGA4 IgM antibody levels are not significantly higher in MS patients, which could potentially explain the poor selectivity of the commercial test. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|